IN2015DN01496A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01496A
IN2015DN01496A IN1496DEN2015A IN2015DN01496A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A IN 1496DEN2015 A IN1496DEN2015 A IN 1496DEN2015A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A
Authority
IN
India
Prior art keywords
cancer
wilfordii
organic solvent
treatment
chemotherapeutic
Prior art date
Application number
Other languages
English (en)
Inventor
Moses Sing Sum Chow
Ying Huang
Jinghua Jeffrey Wang
Ranadheer Ravula
zhi jun Wang
Original Assignee
Univ Western Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Health Sciences filed Critical Univ Western Health Sciences
Publication of IN2015DN01496A publication Critical patent/IN2015DN01496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1496DEN2015 2012-08-19 2013-08-19 IN2015DN01496A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (1)

Publication Number Publication Date
IN2015DN01496A true IN2015DN01496A (enrdf_load_stackoverflow) 2015-07-03

Family

ID=50150329

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1496DEN2015 IN2015DN01496A (enrdf_load_stackoverflow) 2012-08-19 2013-08-19

Country Status (9)

Country Link
US (1) US10149876B2 (enrdf_load_stackoverflow)
EP (1) EP2888011A4 (enrdf_load_stackoverflow)
JP (1) JP6367801B2 (enrdf_load_stackoverflow)
CN (1) CN104797296B (enrdf_load_stackoverflow)
AU (2) AU2013306058A1 (enrdf_load_stackoverflow)
CA (1) CA2880575C (enrdf_load_stackoverflow)
HK (2) HK1211888A1 (enrdf_load_stackoverflow)
IN (1) IN2015DN01496A (enrdf_load_stackoverflow)
WO (1) WO2014031543A1 (enrdf_load_stackoverflow)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225332A1 (zh) * 2013-09-13 2017-09-08 健康科学西部大学 用於克服化学治疗抗性的雷公藤内酯甲
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013627A1 (en) 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
JP2004075888A (ja) * 2002-08-20 2004-03-11 Konica Minolta Holdings Inc 蛍光塗料または蛍光インク並びに蛍光画像及びその形成方法
JPWO2004075888A1 (ja) 2003-02-27 2006-06-01 輝夫 西田 角膜潰瘍治療剤
CN102443039B (zh) * 2010-10-14 2013-11-13 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Also Published As

Publication number Publication date
AU2013306058A1 (en) 2015-02-19
CN104797296A (zh) 2015-07-22
JP6367801B2 (ja) 2018-08-01
CN104797296B (zh) 2019-12-17
EP2888011A4 (en) 2016-01-27
EP2888011A1 (en) 2015-07-01
HK1211888A1 (en) 2016-06-03
JP2015529664A (ja) 2015-10-08
US10149876B2 (en) 2018-12-11
HK1212270A1 (en) 2016-06-10
AU2018200709B2 (en) 2019-10-24
US20150238553A1 (en) 2015-08-27
CA2880575A1 (en) 2014-02-27
CA2880575C (en) 2023-07-11
WO2014031543A1 (en) 2014-02-27
AU2018200709A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
MX2019012462A (es) Terapia combinada.
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
NZ729643A (en) Combination therapy for treating cancer
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
WO2007084670A8 (en) Specific therapy using integrin ligands for treating cancer
WO2016025635A3 (en) Combination therapy for treating cancer
PH12014501560A1 (en) Carbamate compounds and of making and using same
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
WO2011017534A3 (en) Treatment of prostate cancer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
IN2015DN01496A (enrdf_load_stackoverflow)
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
JP2015529664A5 (enrdf_load_stackoverflow)